|  |  | 

India Top Headlines

In the process of applying for the emergency use of ‘Covishield’ in the next 2 weeks, says CEO of Serum | India News


NEW DELHI: The Serum Institute of India is in the process of applying for Covishield’s emergency use authorization in the next two weeks, said CEO Adar Poonawalla.
After holding a review meeting on Saturday with Prime Minister Narendra Modi, Poonawalla said: “All over the world, everyone is now dependent and looking forward to vaccines coming out in large volumes and at an affordable price from India as everyone already knows that more than 50 to 60 percent of all vaccines are made in India. ”
“For now, we have nothing in writing with the government of India on how many doses they will buy, but the indication is that it would be 300 to 400 million doses by July 2021,” he added.

Earlier today PM Modi visited the Serum Institute of India and reviewed the progress of the ‘Covishield’ vaccine that is being made there.
Modi interacted with scientists at the Serum Institute and toured the facility, taking stock of the vaccine development work that is taking place there.
Speaking about the discussion with the prime minister, Poonawalla said: “Prime Minister Modi is now extremely knowledgeable about vaccines and vaccine production. We were surprised by what he already knew. There was very little to explain to him except to go into detail about different variable vaccines and the challenges they may face in the future, “said Poonawalla.
Poonawalla also said that the vaccine will be distributed first in India and then in COVAX countries, which are mainly located in Africa, adding that AstraZeneca and Oxford handle the UK and European markets.
Serum Institute of India has partnered with global pharmaceutical giant AstraZeneca and the University of Oxford for the vaccine.

Times of India